Your browser doesn't support javascript.
loading
IRF2 is a master regulator of human keratinocyte stem cell fate.
Mercado, Nicolas; Schutzius, Gabi; Kolter, Christian; Estoppey, David; Bergling, Sebastian; Roma, Guglielmo; Gubser Keller, Caroline; Nigsch, Florian; Salathe, Adrian; Terranova, Remi; Reece-Hoyes, John; Alford, John; Russ, Carsten; Knehr, Judith; Hoepfner, Dominic; Aebi, Alexandra; Ruffner, Heinz; Beck, Tanner C; Jagannathan, Sajjeev; Olson, Calla M; Sheppard, Hadley E; Elsarrag, Selma Z; Bouwmeester, Tewis; Frederiksen, Mathias; Lohmann, Felix; Lin, Charles Y; Kirkland, Susan.
Afiliación
  • Mercado N; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Schutzius G; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Kolter C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Estoppey D; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Bergling S; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Roma G; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Gubser Keller C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Nigsch F; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Salathe A; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Terranova R; Preclinical Safety, Translational Medicine, NIBR, Basel, CH-4057, Switzerland.
  • Reece-Hoyes J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Alford J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Russ C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Knehr J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Hoepfner D; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Aebi A; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Ruffner H; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Beck TC; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Jagannathan S; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Olson CM; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Sheppard HE; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Elsarrag SZ; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Bouwmeester T; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Frederiksen M; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Lohmann F; Autoimmunity, Transplantation and Inflammation, NIBR, Basel, CH-4056, Switzerland. Felix.Lohmann@novartis.com.
  • Lin CY; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Charles.Y.Lin@bcm.edu.
  • Kirkland S; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Charles.Y.Lin@bcm.edu.
Nat Commun ; 10(1): 4676, 2019 10 14.
Article en En | MEDLINE | ID: mdl-31611556
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Madre / Queratinocitos / Factor 2 Regulador del Interferón Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Madre / Queratinocitos / Factor 2 Regulador del Interferón Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article